Opioid and Cannabinoid Pharmacokinetic Interactions

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00308555
First received: March 27, 2006
Last updated: May 28, 2013
Last verified: May 2013
  Purpose

We are conducting a study to assess whether smoking marijuana affects the safety of prescribed opioids in patients treated for cancer-related pain. This study will assess whether smoking cannabis affects the absorption, distribution, metabolism and excretion of widely used opioid analgesics. We propose to do this by investigating the effects of smoked cannabis in subjects prescribed morphine or oxycodone for cancer-related pain. We will also assess the clinical safety of cannabinoids and these opioids by monitoring the short-term side effects associated with combined therapy.


Condition Intervention Phase
Pain
Neoplasms
Drug: Cannabis
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Opioid and Cannabinoid Pharmacokinetic Interactions: A Pilot Study

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use [ Time Frame: Day 1, Day 5 ] [ Designated as safety issue: No ]
    Pharmacokinetics are measured on Day 1, prior to cannabis use, and again on Day 5, following cannabis use on Days 2, 3, and 4.


Enrollment: 24
Study Start Date: May 2006
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Cannabis Drug: Cannabis

Detailed Description:

Chronic pain conditions remain problematic, especially in patients with cancer. Although opioids are effective analgesics, dose-limiting side effects in the form of sedation, nausea and vomiting, and fear of dependence often limit their use at higher - and possibly more effective - doses. Of particular interest, however, is the potential for greater than additive analgesic effect of cannabinoids and opioids in combination that would allow for opioid analgesic effect to be achieved at lower dosages than are necessary alone, which could overcome problems with both tolerance and side effects for both drug classes. Unfortunately, safety data on the combination in humans does not exist at this time and needs to be obtained. As increasing numbers of patients with cancer may turn to cannabis to augment the effects of their opioid analgesics, data on potential pharmacokinetic interactions and clinical safety of the combinations should be evaluated in a controlled clinical research setting.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ongoing analgesic therapy with either oxycodone hydrochloride (OxyContin) or morphine sulfate (MS Contin) every 12 hours for cancer pain.
  2. Eligible subjects will be ³ 18 years of age with a diagnosis of cancer and an estimated survival of greater than six months.
  3. Subjects must be on a stable dose of opioid medication for at least 2 weeks before enrollment.
  4. Current other analgesic medications will be maintained during the study. The subject must have been on a stable medication regimen for at least 2 weeks.
  5. The following laboratory parameters documented within 45 days prior to study entry:

    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) £ 5 X upper limit of normal (ULN)
    • Total bilirubin £ 2 X ULN
    • Creatinine £ 2.0 mg/dL (177 µmol/L)
  6. All men and women in this study must agree to use adequate birth control during this study. Acceptable barrier birth control methods are a male condom, female condom, diaphragm, or intra-uterine (IUD).
  7. All women of reproductive potential (who have not reached menopause or undergone hysterectomy, oophorectomy, or tubal ligation) must have a negative urine b-HCG pregnancy test performed before initiating the protocol-specified medication.
  8. Prior history of use of marijuana. Subjects must have smoked marijuana on at least 6 occasions in their lifetime prior to enrollment.
  9. Able to understand and follow the instructions of the investigator, including completing the pain intensity rating scales.
  10. Karnofsky Performance Score >60.
  11. Able and willing to provide informed consent.

Exclusion Criteria:

  1. Severe coronary artery disease, uncontrolled hypertension, cardiac ventricular conduction abnormalities, or orthostatic mean blood pressure drop greater than 24 mmHg, severe chronic obstructive pulmonary disease.
  2. History of renal or hepatic failure.
  3. Evidence of hepatic, hematological or renal dysfunction based on judgment of physician.
  4. Active substance abuse (e.g., alcohol or injection drugs).
  5. Use of smoked marijuana within 30 days of enrollment verified with a urine THC level.
  6. Neurologic dysfunction or psychiatric disorder severe enough to interfere with assessment of pain or sensory systems.
  7. Current use of smoked tobacco products or a confirmed cotinine level.
  8. Women who are pregnant or breast-feeding may not take part in this study.
  9. Unable to read or speak English.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00308555

Locations
United States, California
Community Consortium
San Francisco, California, United States, 94110
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Donald I Abrams, M.D. University of California, San Francisco
  More Information

No publications provided

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00308555     History of Changes
Other Study ID Numbers: CC # 064, 1 R21 DA 020831-01
Study First Received: March 27, 2006
Results First Received: May 23, 2013
Last Updated: May 28, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Francisco:
Cancer pain
Cannabis
Morphine
Oxycodone
Marijuana
Cancer-related pain

ClinicalTrials.gov processed this record on October 22, 2014